• Je něco špatně v tomto záznamu ?

Antistaphylococcal discovery pipeline; where are we now

D. Nawrot, W. Ambrożkiewicz-Mosler, M. Doležal, G. Bouz

. 2024 ; 266 (-) : 116077. [pub] 20231220

Jazyk angličtina Země Francie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007124

The serious spread of antibiotic-resistant Staphylococcal aureus strains is alarming. This is reflected by the measures governments and health-related bodies are offering to ease antibiotic drug development. Finding new active agents, preferably with novel mechanism of action, or even finding new targets for drug development are essential. In this review, we summarize the current status of novel antistaphylococcal agents undergoing clinical trials. We mainly discuss antistaphylococcal small molecules and peptides in the text with a special focus on their chemistry, while antistaphylococcal immunotherapy (antibodies) are mentioned in a summative table. This review shall serve as a summary that influences future synthetic efforts in the antistaphyloccocals development field.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007124
003      
CZ-PrNML
005      
20240522135128.0
007      
ta
008      
240412e20231220fr f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ejmech.2023.116077 $2 doi
035    __
$a (PubMed)38219657
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a fr
100    1_
$a Nawrot, Daria $u Faculty of Pharmacy in Hradec Králové, Charles University, 50005, Hradec Králové, Czech Republic. Electronic address: nawrotd@faf.cuni.cz
245    10
$a Antistaphylococcal discovery pipeline; where are we now / $c D. Nawrot, W. Ambrożkiewicz-Mosler, M. Doležal, G. Bouz
520    9_
$a The serious spread of antibiotic-resistant Staphylococcal aureus strains is alarming. This is reflected by the measures governments and health-related bodies are offering to ease antibiotic drug development. Finding new active agents, preferably with novel mechanism of action, or even finding new targets for drug development are essential. In this review, we summarize the current status of novel antistaphylococcal agents undergoing clinical trials. We mainly discuss antistaphylococcal small molecules and peptides in the text with a special focus on their chemistry, while antistaphylococcal immunotherapy (antibodies) are mentioned in a summative table. This review shall serve as a summary that influences future synthetic efforts in the antistaphyloccocals development field.
650    _2
$a lidé $7 D006801
650    12
$a antibakteriální látky $x farmakologie $x terapeutické užití $7 D000900
650    _2
$a Staphylococcus aureus $7 D013211
650    12
$a stafylokokové infekce $x farmakoterapie $7 D013203
650    _2
$a peptidy $x terapeutické užití $7 D010455
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Ambrożkiewicz-Mosler, Weronika $u Faculty of Pharmacy in Hradec Králové, Charles University, 50005, Hradec Králové, Czech Republic
700    1_
$a Doležal, Martin, $d 1961- $u Faculty of Pharmacy in Hradec Králové, Charles University, 50005, Hradec Králové, Czech Republic $7 jn19981000714
700    1_
$a Bouz, Ghada $u Faculty of Pharmacy in Hradec Králové, Charles University, 50005, Hradec Králové, Czech Republic. Electronic address: bouzg@faf.cuni.cz
773    0_
$w MED00001628 $t European journal of medicinal chemistry $x 1768-3254 $g Roč. 266 (20231220), s. 116077
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38219657 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240522135123 $b ABA008
999    __
$a ok $b bmc $g 2081239 $s 1216891
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 266 $c - $d 116077 $e 20231220 $i 1768-3254 $m European journal of medicinal chemistry $n Eur J Med Chem $x MED00001628
LZP    __
$a Pubmed-20240412
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace